Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention-Reference-Cited by-同舟云学术

Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention

Published:2012-05 Issue:5 Volume:129 Page:623-628
ISSN:0049-3848
Container-title:Thrombosis Research
language:en
Short-container-title:Thrombosis Research

Author:

Yokoi Hiroyoshi,Kimura Takeshi,Isshiki Takaaki,Ogawa Hisao,Ikeda Yasuo

Publisher

Elsevier BV

Subject

Hematology

Reference15 articles.

1. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis;Combescure;J Thromb Haemost,2010

2. Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile;Jakubowski;Cardiovasc Drug Rev,2007

3. A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation;Brandt;Am Heart J,2007

4. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin treated patients with stable coronary artery disease;Jernberg;Eur Heart J,2006

5. Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcomes of adjusted-dose versus standard-dose prasugrel in East Asian patients with acute myocardial infarction;International Journal of Cardiology;2024-09

2. Ticagrelor versus Adjusted‐Dose Prasugrel in Acute Coronary Syndrome with Percutaneous Coronary Intervention;Clinical Pharmacology & Therapeutics;2024-02-19

3. Clinical Outcomes of Adjusted-Dose Versus Standard-Dose Prasugrel in East Asian Patients with Acute Myocardial Infarction;2024

4. De-escalation of Antiplatelet Therapy After Percutaneous Coronary Intervention in East Asian Patients With Acute Coronary Syndrome;Clinical Therapeutics;2023-12

5. De-Escalation Therapy After PCI in ACS Patients With Chronic Kidney Disease;JACC: Asia;2023-02